How to manage norovirus infection in transplant patients?

Question

Hello doctor,

A 42-year-old female, 15 days post-allogeneic transplant, presents with severe secretory diarrhea exceeding 4 liters per day due to norovirus infection. The patient has an absolute neutrophil count of zero and requires daily platelet transfusions. Cyclosporine levels are undetectable. A CT scan reveals a thickening of the bowel wall. Total parenteral nutrition (TPN) has been initiated, but the patient is developing line sepsis. A recent endoscopy indicates severe gut graft-versus-host disease (GVHD) versus viral damage. Stool polymerase chain reaction (PCR) testing shows a significant viral load. Should octreotide be considered?

Kindly help.

Answer 1

Hello;

Welcome to icliniq.com.

I read your query and can understand your concern.

A patient undergoing bone marrow transplantation (BMT) who presents with norovirus, severe neutropenia (absolute neutrophil count of 0), gastrointestinal graft-versus-host disease (GVHD) versus viral enteritis, and sepsis associated with total parenteral nutrition (TPN) represents a case of extremely high risk. The management of norovirus in an immunocompromised individual is particularly complex, as the resolution of the virus is contingent upon immune recovery, which is hindered by GVHD and ongoing immunosuppressive therapy.

Administering an injection of octreotide (a peptide drug, 50–100 mcg every 8 hours) is a viable strategy to manage severe secretory diarrhea.

A cyclosporine level that is undetectable may indicate a potential flare of GVHD, which could exacerbate intestinal damage. In cases of severe gut GVHD, the use of steroids (methylprednisolone at 1–2 mg/kg/day) or ruxolitinib may be warranted.

Fecal microbiota transplantation (FMT) should be considered for viral enteritis if the GVHD is under control.

If line sepsis is confirmed, it may be necessary to remove the catheter if it is clinically appropriate. Blood cultures should be obtained, and broad-spectrum antibiotics should be initiated until culture results are available, at which point specific antibiotics can be started. Additionally, evaluate for co-infections with cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus.

While TPN is crucial for nutrition, it also heightens the risk of sepsis. If tolerated, consider implementing trophic enteral feeds. Regular monitoring of electrolytes (potassium, magnesium, phosphate) is essential. Intravenous immunoglobulin (IVIG) may be beneficial in cases of compromised immunity.

This situation is critical, necessitating collaboration with both a hematologist and a gastroenterologist. It is imperative to contact both specialists to assess the patient and develop a comprehensive treatment plan together. Laboratory results alone may not provide sufficient information; a thorough physical examination of the patient is essential, thus face-to-face consultations are required.

I hope this information helps you.

Thank you.